DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Unified Data-Tech IPO opens for subscription : Check GMP, price band and others
22/05/2025
Dollar swoons on fiscal worries, bitcoin extends record rally
22/05/2025
Wall Street stocks tumble as worries mount about US debt
22/05/2025
Indian IPO market gains momentum with 7 cos launching offerings in May
22/05/2025
Why is Groww raising brokerage fees by 150% for small trades ?
22/05/2025
Why are foreign investors flocking to BFSI stocks in May ?
22/05/2025
